Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Monoamine oxidase inhibition by Rhodiola rosea L. roots.

van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K.

J Ethnopharmacol. 2009 Mar 18;122(2):397-401. doi: 10.1016/j.jep.2009.01.007.

PMID:
19168123
2.

Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase A inhibitors.

Chimenti F, Bolasco A, Manna F, Secci D, Chimenti P, Granese A, Befani O, Turini P, Cirilli R, La Torre F, Alcaro S, Ortuso F, Langer T.

Curr Med Chem. 2006;13(12):1411-28. Review.

PMID:
16719786
3.

Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy.

Panossian A, Wikman G, Sarris J.

Phytomedicine. 2010 Jun;17(7):481-93. doi: 10.1016/j.phymed.2010.02.002. Review.

PMID:
20378318
4.

Monoamine oxidases: to inhibit or not to inhibit.

Ramsay RR, Gravestock MB.

Mini Rev Med Chem. 2003 Mar;3(2):129-36. Review.

PMID:
12570845
5.

Does Rhodiola rosea possess ergogenic properties?

Walker TB, Robergs RA.

Int J Sport Nutr Exerc Metab. 2006 Jun;16(3):305-15. Review.

PMID:
16948486
6.

Rhodiola rosea: a possible plant adaptogen.

Kelly GS.

Altern Med Rev. 2001 Jun;6(3):293-302. Review.

7.

Herbal natural products as a source of monoamine oxidase inhibitors: a review.

Viña D, Serra S, Lamela M, Delogu G.

Curr Top Med Chem. 2012;12(20):2131-44. Review.

PMID:
23231392
8.

Monoamine oxidase-B inhibition in Alzheimer's disease.

Riederer P, Danielczyk W, Grünblatt E.

Neurotoxicology. 2004 Jan;25(1-2):271-7. Review.

PMID:
14697902
9.

Perspective on Roseroot (Rhodiola rosea) studies.

Blomkvist J, Taube A, Larhammar D.

Planta Med. 2009 Sep;75(11):1187-90. doi: 10.1055/s-0029-1185720. Review.

PMID:
19468971
10.

Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction.

van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A.

Life Sci. 2006 Oct 19;79(21):1969-73. Review.

PMID:
16884739
11.

Monoamine oxidase inhibition.

Tipton KF.

Biochem Soc Trans. 1994 Aug;22(3):764-8. Review. No abstract available.

PMID:
7821681
12.

Perspectives on MAO-B in aging and neurological disease: where do we go from here?

Kumar MJ, Andersen JK.

Mol Neurobiol. 2004 Aug;30(1):77-89. Review.

PMID:
15247489
13.

Anti-dipsotropic isoflavones: the potential therapeutic agents for alcohol dependence.

Keung WM.

Med Res Rev. 2003 Nov;23(6):669-96. Review.

PMID:
12939789
14.

Rhodiola rosea L. and Alzheimer's Disease: From Farm to Pharmacy.

Nabavi SF, Braidy N, Orhan IE, Badiee A, Daglia M, Nabavi SM.

Phytother Res. 2016 Apr;30(4):532-9. doi: 10.1002/ptr.5569. Review.

PMID:
27059687
15.

The relationship of early studies of monoamine oxidase to present concepts.

Kopin IJ.

J Neural Transm Suppl. 2006;(71):79-86. Review.

PMID:
17447418
16.

Tribulin and endogenous MAO-inhibitory regulation in vivo.

Medvedev AE, Glover V.

Neurotoxicology. 2004 Jan;25(1-2):185-92. Review.

PMID:
14697893
17.

[Experimental analysis of therapeutic properties of Rhodiola rosea L. and its possible application in medicine].

Kucinskaite A, Briedis V, Savickas A.

Medicina (Kaunas). 2004;40(7):614-9. Review. Lithuanian.

18.

Computer modelling and visualization of active site of monoamine oxidases.

Veselovsky AV, Ivanov AS, Medvedev AE.

Neurotoxicology. 2004 Jan;25(1-2):37-46. Review.

PMID:
14697879
19.

Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.

Bainbridge JL, Page RL 2nd, Ruscin JM.

Neurol Clin. 2008 Aug;26(3 Suppl):S85-96, vi. doi: 10.1016/j.ncl.2008.05.002. Review.

PMID:
18774444
20.

The therapeutic potential of monoamine oxidase inhibitors.

Youdim MB, Edmondson D, Tipton KF.

Nat Rev Neurosci. 2006 Apr;7(4):295-309. Review.

PMID:
16552415

Supplemental Content

Support Center